Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Symptoms include bloating, cramping, fatigue, heartburn, vomiting, weakness and diarrhea. Complications of short bowel syndrome include malnutrition, peptic ulcers, kidney stones and small intestinal bacterial overgrowth. Treatment includes vitamin and mineral supplements, antibiotics, proton pump inhibitors and bile-salt binders.
This Pharmaceutical and Healthcare latest pipeline guide Short Bowel Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Short Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Short Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Short Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 3, 1, 7 and 1 respectively.
Short Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Short Bowel Syndrome (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Short Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Short Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Short Bowel Syndrome (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Short Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Report Coverage
- Short Bowel Syndrome - Overview
- Short Bowel Syndrome - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Short Bowel Syndrome - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Short Bowel Syndrome - Companies Involved in Therapeutics Development
- Adocia SAS
- enGene Inc
- Hanmi Pharmaceuticals Co Ltd
- Huons Global Co Ltd
- Micelle BioPharma Inc
- Naia Rare Diseases Inc
- OPKO Health Inc
- Pfizer Inc
- PhaseBio Pharmaceuticals Inc
- Takeda Pharmaceutical Co Ltd
- Worphmed Srl
- Zealand Pharma AS
- Short Bowel Syndrome - Drug Profiles
- apraglutide - Drug Profile
- exenatide - Drug Profile
- Fusion Protein to Agonize GLP2R for Short Bowel Syndrome - Drug Profile
- Gene Therapy for Short Bowel Syndrome - Drug Profile
- glepaglutide - Drug Profile
- HL-06 - Drug Profile
- HM-15912 - Drug Profile
- melatonin - Drug Profile
- MOD-1501 - Drug Profile
- NB-1002 - Drug Profile
- SC-403 - Drug Profile
- TAK-681 - Drug Profile
- teduglutide - Drug Profile
- teduglutide - Drug Profile
- ZP-7570 - Drug Profile
- Short Bowel Syndrome - Dormant Projects
- Short Bowel Syndrome - Discontinued Products
- Short Bowel Syndrome - Product Development Milestones
- Featured News & Press Releases
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/kqsequ